Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 5/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 13/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | KIT | P10721 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.40 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21873140 | 0.86 | GPR84 (0.46) | CSF1RPDGFRAPDGFRBKDRCYP3A4 | |
| SCHEMBL21873010 | 0.85 | CSF1R (0.46) | CSF1RPDGFRAPDGFRBKDRCYP3A4 | |
| SCHEMBL21873093 | 0.85 | CSF1R (0.44) | CSF1RPDGFRAPDGFRBKDRCYP3A4 | |
| SCHEMBL21872979 | 0.80 | CYP3A4 (0.47) | CSF1RKDRCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL21965142 | 0.78 | CSF1R (0.42) | CSF1RPDGFRAPDGFRBKDRFLT3 | |
| SCHEMBL21872989 | 0.75 | CYP3A4 (0.37) | CSF1RKDRCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL28337392 | 0.73 | CSF1R (0.45) | CSF1RPDGFRAPDGFRBKDRFLT3 | |
| SCHEMBL21873024 | 0.73 | CSF1R (0.44) | CSF1RPDGFRAPDGFRBKDRFLT3 | |
| SCHEMBL21873162 | 0.72 | CYP3A4 (0.52) | CSF1RKDRCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL21873065 | 0.71 | CSF1R (0.47) | CSF1RPDGFRAPDGFRBKDRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180495-B2 | Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-11-23 | — | — | US | disclosed |
| US-20200140431-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2020-05-07 | — | — | US | disclosed |
| EP-3643715-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2020-04-29 | — | — | EP | disclosed |
| EP-3643715-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2020-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140431-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | CSF1R, CSF3R, FSHR | CSF1R 1/4885PDGFRA 229/4885PDGFRB 149/4885 |
| US-11180495-B2 | Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof | CSF1R, CSF3R, FSHR | CSF1R 1/4885PDGFRA 229/4885PDGFRB 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.